| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Drug-Eluting Stents | 14 | 2019 | 562 | 2.06 | Why? |
| Percutaneous Coronary Intervention | 26 | 2019 | 3646 | 1.63 | Why? |
| Low Back Pain | 4 | 2019 | 190 | 1.43 | Why? |
| Coronary Artery Disease | 21 | 2019 | 2570 | 1.41 | Why? |
| Fractional Flow Reserve, Myocardial | 9 | 2019 | 173 | 1.25 | Why? |
| Chronic Pain | 4 | 2019 | 736 | 0.96 | Why? |
| Pain Threshold | 4 | 2019 | 46 | 0.92 | Why? |
| Acute Coronary Syndrome | 10 | 2019 | 2107 | 0.89 | Why? |
| Reflex | 2 | 2017 | 22 | 0.86 | Why? |
| Absorbable Implants | 7 | 2019 | 191 | 0.82 | Why? |
| Myocardial Revascularization | 6 | 2019 | 267 | 0.80 | Why? |
| Everolimus | 7 | 2019 | 215 | 0.72 | Why? |
| Norfloxacin | 1 | 2017 | 13 | 0.72 | Why? |
| Transcatheter Aortic Valve Replacement | 5 | 2019 | 839 | 0.72 | Why? |
| Hospitals, Proprietary | 1 | 2017 | 1 | 0.70 | Why? |
| Coronary Artery Bypass | 4 | 2019 | 629 | 0.69 | Why? |
| Hospitals, Voluntary | 1 | 2017 | 11 | 0.69 | Why? |
| Coronary Angiography | 14 | 2019 | 2275 | 0.65 | Why? |
| Injections, Intra-Articular | 1 | 2016 | 104 | 0.64 | Why? |
| Cesarean Section | 2 | 2017 | 2089 | 0.64 | Why? |
| Randomized Controlled Trials as Topic | 20 | 2021 | 10649 | 0.61 | Why? |
| Acute Pain | 1 | 2016 | 73 | 0.60 | Why? |
| Heart Valve Prosthesis | 3 | 2019 | 533 | 0.58 | Why? |
| Cardiovascular Agents | 5 | 2019 | 663 | 0.58 | Why? |
| Private Sector | 1 | 2017 | 262 | 0.57 | Why? |
| Aortic Valve Stenosis | 3 | 2019 | 741 | 0.57 | Why? |
| Climate | 1 | 2020 | 557 | 0.57 | Why? |
| Knee Joint | 1 | 2016 | 194 | 0.56 | Why? |
| Heart Valve Prosthesis Implantation | 3 | 2019 | 552 | 0.56 | Why? |
| Sirolimus | 5 | 2019 | 240 | 0.56 | Why? |
| Pain Measurement | 5 | 2017 | 533 | 0.56 | Why? |
| Urinary Tract Infections | 1 | 2017 | 534 | 0.46 | Why? |
| Insurance, Health | 1 | 2017 | 634 | 0.45 | Why? |
| Cardiac Surgical Procedures | 6 | 2021 | 1931 | 0.43 | Why? |
| Hospitals, Public | 1 | 2017 | 774 | 0.42 | Why? |
| Erythrocyte Transfusion | 3 | 2019 | 386 | 0.41 | Why? |
| Platelet Aggregation Inhibitors | 7 | 2019 | 1671 | 0.40 | Why? |
| Myocardial Infarction | 13 | 2019 | 3361 | 0.40 | Why? |
| Radial Artery | 3 | 2019 | 132 | 0.37 | Why? |
| Hemorrhage | 3 | 2021 | 3013 | 0.36 | Why? |
| Femoral Artery | 3 | 2019 | 213 | 0.34 | Why? |
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 1454 | 0.34 | Why? |
| Aortic Valve | 3 | 2019 | 664 | 0.34 | Why? |
| Blood Coagulation Disorders | 1 | 2021 | 2040 | 0.33 | Why? |
| Purinergic P2Y Receptor Antagonists | 2 | 2019 | 206 | 0.33 | Why? |
| Coated Materials, Biocompatible | 2 | 2018 | 113 | 0.33 | Why? |
| Bioprosthesis | 2 | 2018 | 126 | 0.31 | Why? |
| Cardiology | 5 | 2019 | 2873 | 0.31 | Why? |
| Societies, Medical | 5 | 2019 | 6907 | 0.28 | Why? |
| Switzerland | 8 | 2021 | 2738 | 0.28 | Why? |
| Coronary Stenosis | 2 | 2018 | 273 | 0.27 | Why? |
| Prosthesis Design | 4 | 2019 | 594 | 0.27 | Why? |
| Primary Health Care | 2 | 2019 | 4839 | 0.25 | Why? |
| Treatment Outcome | 25 | 2021 | 51732 | 0.25 | Why? |
| Anticoagulants | 2 | 2021 | 9563 | 0.24 | Why? |
| Aspirin | 3 | 2019 | 1043 | 0.24 | Why? |
| Troponin T | 2 | 2017 | 771 | 0.22 | Why? |
| Single-Blind Method | 3 | 2019 | 1283 | 0.21 | Why? |
| Intention to Treat Analysis | 5 | 2021 | 673 | 0.21 | Why? |
| Failed Back Surgery Syndrome | 1 | 2019 | 4 | 0.21 | Why? |
| Ambulatory Care | 1 | 2017 | 4947 | 0.21 | Why? |
| Polymers | 3 | 2019 | 507 | 0.20 | Why? |
| Prospective Studies | 20 | 2020 | 43301 | 0.20 | Why? |
| Atrial Flutter | 1 | 2021 | 143 | 0.20 | Why? |
| Femoracetabular Impingement | 1 | 2018 | 4 | 0.20 | Why? |
| Electrocardiography, Ambulatory | 1 | 2021 | 204 | 0.20 | Why? |
| Tissue Scaffolds | 2 | 2018 | 174 | 0.20 | Why? |
| Acetabulum | 1 | 2018 | 18 | 0.20 | Why? |
| Acute Kidney Injury | 2 | 2019 | 5762 | 0.19 | Why? |
| Humans | 88 | 2021 | 930598 | 0.19 | Why? |
| Coronary Vessels | 2 | 2017 | 914 | 0.19 | Why? |
| Pragmatic Clinical Trials as Topic | 1 | 2021 | 350 | 0.19 | Why? |
| Seminoma | 1 | 2018 | 16 | 0.19 | Why? |
| Hip Joint | 1 | 2018 | 59 | 0.19 | Why? |
| Cysteine-Rich Protein 61 | 1 | 2017 | 2 | 0.19 | Why? |
| Diabetic Cardiomyopathies | 1 | 2019 | 79 | 0.18 | Why? |
| Angina, Stable | 1 | 2018 | 45 | 0.18 | Why? |
| Medication Adherence | 2 | 2019 | 1270 | 0.18 | Why? |
| Controlled Clinical Trials as Topic | 1 | 2018 | 53 | 0.18 | Why? |
| Hemoglobins | 3 | 2019 | 958 | 0.18 | Why? |
| Postoperative Complications | 8 | 2021 | 5861 | 0.18 | Why? |
| Nociceptive Pain | 1 | 2017 | 8 | 0.18 | Why? |
| Chordae Tendineae | 1 | 2017 | 14 | 0.18 | Why? |
| Coronary Thrombosis | 3 | 2018 | 433 | 0.18 | Why? |
| Public Health | 3 | 2021 | 16359 | 0.18 | Why? |
| Hematinics | 1 | 2017 | 48 | 0.18 | Why? |
| Oxycodone | 1 | 2017 | 18 | 0.18 | Why? |
| Reaction Time | 1 | 2017 | 96 | 0.17 | Why? |
| Sciatica | 1 | 2016 | 6 | 0.17 | Why? |
| Mitral Valve Prolapse | 1 | 2017 | 24 | 0.17 | Why? |
| Mitral Valve Stenosis | 1 | 2017 | 29 | 0.17 | Why? |
| Diskectomy | 1 | 2016 | 12 | 0.17 | Why? |
| ST Elevation Myocardial Infarction | 3 | 2019 | 3051 | 0.17 | Why? |
| Internal Mammary-Coronary Artery Anastomosis | 1 | 2016 | 11 | 0.17 | Why? |
| Testicular Neoplasms | 1 | 2018 | 91 | 0.17 | Why? |
| Physical Stimulation | 1 | 2016 | 42 | 0.17 | Why? |
| Neoplasms, Germ Cell and Embryonal | 1 | 2018 | 106 | 0.17 | Why? |
| Medical Record Linkage | 1 | 2017 | 58 | 0.17 | Why? |
| Intervertebral Disc Displacement | 1 | 2016 | 25 | 0.17 | Why? |
| Research Report | 1 | 2021 | 376 | 0.16 | Why? |
| Psychophysics | 1 | 2016 | 56 | 0.16 | Why? |
| Guidelines as Topic | 2 | 2021 | 2844 | 0.16 | Why? |
| Clinical Trials, Phase III as Topic | 1 | 2021 | 782 | 0.16 | Why? |
| Angioplasty | 1 | 2017 | 106 | 0.16 | Why? |
| Review Literature as Topic | 2 | 2017 | 387 | 0.16 | Why? |
| Publication Bias | 1 | 2017 | 241 | 0.16 | Why? |
| Solubility | 1 | 2017 | 382 | 0.16 | Why? |
| Post-Exposure Prophylaxis | 1 | 2021 | 472 | 0.16 | Why? |
| Benzhydryl Compounds | 1 | 2019 | 240 | 0.16 | Why? |
| Analgesics, Non-Narcotic | 1 | 2017 | 164 | 0.16 | Why? |
| Radiation Protection | 1 | 2017 | 78 | 0.15 | Why? |
| Health Care Costs | 3 | 2019 | 1007 | 0.15 | Why? |
| Metals | 1 | 2018 | 182 | 0.15 | Why? |
| Back Pain | 1 | 2016 | 115 | 0.15 | Why? |
| Coronary Disease | 2 | 2019 | 645 | 0.15 | Why? |
| Ventricular Remodeling | 1 | 2019 | 349 | 0.15 | Why? |
| Drugs, Essential | 1 | 2017 | 117 | 0.15 | Why? |
| Anti-Bacterial Agents | 1 | 2017 | 10083 | 0.15 | Why? |
| Lumbar Vertebrae | 1 | 2016 | 196 | 0.14 | Why? |
| Glucosides | 1 | 2019 | 359 | 0.14 | Why? |
| Radiation Exposure | 1 | 2017 | 161 | 0.14 | Why? |
| Dexamethasone | 3 | 2020 | 2055 | 0.14 | Why? |
| Editorial Policies | 1 | 2020 | 408 | 0.14 | Why? |
| Female | 41 | 2021 | 380317 | 0.14 | Why? |
| Allografts | 1 | 2018 | 761 | 0.14 | Why? |
| Glucocorticoids | 2 | 2020 | 4431 | 0.14 | Why? |
| Adenosine | 1 | 2018 | 509 | 0.14 | Why? |
| Statistics as Topic | 1 | 2017 | 370 | 0.14 | Why? |
| Osteoarthritis, Knee | 1 | 2016 | 158 | 0.13 | Why? |
| Cardiac Catheterization | 2 | 2018 | 882 | 0.13 | Why? |
| Conservative Treatment | 1 | 2016 | 349 | 0.13 | Why? |
| Middle Aged | 34 | 2019 | 270681 | 0.13 | Why? |
| Catheterization, Peripheral | 1 | 2017 | 249 | 0.13 | Why? |
| Adrenal Cortex Hormones | 3 | 2020 | 6537 | 0.13 | Why? |
| Male | 40 | 2021 | 367725 | 0.12 | Why? |
| Thoracic Surgical Procedures | 1 | 2019 | 504 | 0.12 | Why? |
| Endocarditis, Bacterial | 1 | 2018 | 344 | 0.12 | Why? |
| Mitral Valve Insufficiency | 1 | 2017 | 302 | 0.12 | Why? |
| Combined Modality Therapy | 2 | 2018 | 3395 | 0.12 | Why? |
| Double-Blind Method | 3 | 2019 | 5988 | 0.12 | Why? |
| Coronary Restenosis | 1 | 2014 | 153 | 0.12 | Why? |
| Bayes Theorem | 2 | 2018 | 3237 | 0.12 | Why? |
| Aged | 29 | 2021 | 215776 | 0.12 | Why? |
| Early Termination of Clinical Trials | 1 | 2015 | 1256 | 0.12 | Why? |
| Peripheral Arterial Disease | 1 | 2018 | 471 | 0.12 | Why? |
| Myocardial Ischemia | 1 | 2019 | 781 | 0.11 | Why? |
| Creatinine | 1 | 2018 | 1443 | 0.11 | Why? |
| Stents | 1 | 2019 | 916 | 0.11 | Why? |
| Non-ST Elevated Myocardial Infarction | 1 | 2017 | 490 | 0.11 | Why? |
| Heparin, Low-Molecular-Weight | 1 | 2021 | 1731 | 0.11 | Why? |
| Follow-Up Studies | 10 | 2018 | 17020 | 0.11 | Why? |
| Cardiovascular System | 1 | 2019 | 750 | 0.11 | Why? |
| Bias | 1 | 2017 | 1109 | 0.11 | Why? |
| Pre-Exposure Prophylaxis | 1 | 2020 | 1138 | 0.11 | Why? |
| Neoplasm Staging | 1 | 2018 | 1999 | 0.11 | Why? |
| Patient Readmission | 2 | 2017 | 1543 | 0.11 | Why? |
| Thoracic Surgery | 1 | 2019 | 623 | 0.11 | Why? |
| Neoplasm Recurrence, Local | 1 | 2018 | 1063 | 0.11 | Why? |
| Ventricular Function, Left | 1 | 2019 | 1555 | 0.10 | Why? |
| Cause of Death | 6 | 2020 | 4823 | 0.10 | Why? |
| Educational Measurement | 1 | 2018 | 930 | 0.10 | Why? |
| Diagnostic Imaging | 1 | 2018 | 1044 | 0.10 | Why? |
| Natriuretic Peptide, Brain | 1 | 2016 | 1215 | 0.10 | Why? |
| Time Factors | 11 | 2020 | 31397 | 0.10 | Why? |
| Vascular Surgical Procedures | 1 | 2018 | 882 | 0.10 | Why? |
| Consensus | 3 | 2019 | 6345 | 0.10 | Why? |
| Hypersensitivity | 1 | 2019 | 1137 | 0.09 | Why? |
| General Practice | 1 | 2017 | 718 | 0.09 | Why? |
| Waiting Lists | 1 | 2017 | 1388 | 0.09 | Why? |
| Registries | 6 | 2017 | 12327 | 0.09 | Why? |
| Case-Control Studies | 4 | 2019 | 17671 | 0.09 | Why? |
| Stroke Volume | 1 | 2018 | 2153 | 0.09 | Why? |
| Diabetes Mellitus, Type 2 | 2 | 2019 | 6166 | 0.09 | Why? |
| Heparin | 1 | 2021 | 2600 | 0.09 | Why? |
| Noninvasive Ventilation | 1 | 2021 | 2329 | 0.09 | Why? |
| Community-Acquired Infections | 1 | 2020 | 2328 | 0.09 | Why? |
| Neurosurgical Procedures | 1 | 2019 | 1738 | 0.09 | Why? |
| Analgesics, Opioid | 1 | 2017 | 1070 | 0.08 | Why? |
| Adult | 18 | 2020 | 244371 | 0.08 | Why? |
| Europe | 6 | 2019 | 12702 | 0.08 | Why? |
| Renal Insufficiency | 3 | 2019 | 810 | 0.08 | Why? |
| International Cooperation | 1 | 2020 | 3436 | 0.08 | Why? |
| Cardiopulmonary Bypass | 2 | 2018 | 158 | 0.08 | Why? |
| Quality of Life | 5 | 2018 | 9820 | 0.08 | Why? |
| Atrial Fibrillation | 1 | 2021 | 2320 | 0.08 | Why? |
| Lopinavir | 1 | 2021 | 4308 | 0.08 | Why? |
| Peptide Fragments | 1 | 2016 | 2075 | 0.08 | Why? |
| Ritonavir | 1 | 2021 | 4212 | 0.08 | Why? |
| Predictive Value of Tests | 5 | 2019 | 9537 | 0.08 | Why? |
| Dyspnea | 1 | 2019 | 3847 | 0.07 | Why? |
| Practice Guidelines as Topic | 3 | 2019 | 15421 | 0.07 | Why? |
| Thrombectomy | 1 | 2017 | 2272 | 0.07 | Why? |
| Patient Discharge | 1 | 2021 | 5696 | 0.07 | Why? |
| Pneumonia, Viral | 7 | 2020 | 243684 | 0.07 | Why? |
| Fibrin Fibrinogen Degradation Products | 1 | 2021 | 5993 | 0.07 | Why? |
| Coronavirus Infections | 7 | 2020 | 253789 | 0.07 | Why? |
| Cohort Studies | 5 | 2020 | 36005 | 0.07 | Why? |
| Respiration, Artificial | 2 | 2021 | 22116 | 0.07 | Why? |
| Risk Factors | 12 | 2021 | 71621 | 0.07 | Why? |
| Kaplan-Meier Estimate | 3 | 2018 | 4260 | 0.07 | Why? |
| Hospitalization | 5 | 2021 | 54280 | 0.07 | Why? |
| Pandemics | 9 | 2021 | 389249 | 0.07 | Why? |
| Patient Selection | 2 | 2020 | 4560 | 0.07 | Why? |
| Death | 2 | 2017 | 334 | 0.07 | Why? |
| Canada | 3 | 2021 | 6018 | 0.07 | Why? |
| Carcinoma, Hepatocellular | 1 | 2014 | 1222 | 0.07 | Why? |
| Magnetic Resonance Imaging | 2 | 2018 | 6551 | 0.06 | Why? |
| Surgeons | 1 | 2018 | 2233 | 0.06 | Why? |
| Disease Progression | 2 | 2019 | 13580 | 0.06 | Why? |
| Risk Assessment | 7 | 2020 | 25439 | 0.06 | Why? |
| Venous Thromboembolism | 1 | 2020 | 4273 | 0.06 | Why? |
| Early Detection of Cancer | 1 | 2014 | 1956 | 0.06 | Why? |
| Prognosis | 7 | 2020 | 32490 | 0.06 | Why? |
| Liver Neoplasms | 1 | 2014 | 1666 | 0.06 | Why? |
| Ontario | 2 | 2019 | 1966 | 0.06 | Why? |
| Aged, 80 and over | 11 | 2019 | 88759 | 0.06 | Why? |
| Stroke | 6 | 2021 | 8839 | 0.05 | Why? |
| Mass Screening | 1 | 2021 | 8005 | 0.05 | Why? |
| Anemia | 2 | 2019 | 789 | 0.05 | Why? |
| Models, Statistical | 1 | 2018 | 5312 | 0.05 | Why? |
| Thrombosis | 2 | 2020 | 7504 | 0.05 | Why? |
| Epidemics | 1 | 2021 | 6407 | 0.05 | Why? |
| Epidemiological Monitoring | 1 | 2014 | 3493 | 0.05 | Why? |
| Time-to-Treatment | 1 | 2017 | 5883 | 0.05 | Why? |
| Pneumonia | 1 | 2020 | 5652 | 0.05 | Why? |
| Drug Therapy, Combination | 3 | 2019 | 7268 | 0.05 | Why? |
| C-Reactive Protein | 1 | 2016 | 7972 | 0.05 | Why? |
| Hydrocortisone | 2 | 2020 | 1790 | 0.05 | Why? |
| Cardiovascular Diseases | 3 | 2021 | 11497 | 0.05 | Why? |
| Immunosuppressive Agents | 1 | 2018 | 6331 | 0.05 | Why? |
| Extracorporeal Membrane Oxygenation | 1 | 2018 | 5002 | 0.05 | Why? |
| Methylprednisolone | 2 | 2020 | 2107 | 0.05 | Why? |
| Hip | 1 | 2018 | 29 | 0.05 | Why? |
| Cartilage, Articular | 1 | 2018 | 50 | 0.05 | Why? |
| Global Health | 2 | 2020 | 13911 | 0.05 | Why? |
| Orchiectomy | 1 | 2018 | 63 | 0.05 | Why? |
| Preoperative Period | 1 | 2019 | 271 | 0.05 | Why? |
| Canagliflozin | 1 | 2018 | 56 | 0.05 | Why? |
| Occupational Exposure | 1 | 2017 | 4742 | 0.04 | Why? |
| Sample Size | 1 | 2020 | 518 | 0.04 | Why? |
| Retreatment | 1 | 2018 | 186 | 0.04 | Why? |
| Diabetes Mellitus | 1 | 2020 | 8207 | 0.04 | Why? |
| Electric Stimulation | 1 | 2017 | 84 | 0.04 | Why? |
| Radiotherapy, Adjuvant | 1 | 2018 | 180 | 0.04 | Why? |
| Disease Transmission, Infectious | 1 | 2021 | 9044 | 0.04 | Why? |
| Angina Pectoris | 1 | 2018 | 114 | 0.04 | Why? |
| Interrupted Time Series Analysis | 1 | 2021 | 868 | 0.04 | Why? |
| Administrative Claims, Healthcare | 1 | 2017 | 124 | 0.04 | Why? |
| Ischemic Attack, Transient | 1 | 2021 | 439 | 0.04 | Why? |
| Ticlopidine | 1 | 2018 | 193 | 0.04 | Why? |
| Fluoroscopy | 1 | 2017 | 140 | 0.04 | Why? |
| Prosthesis Failure | 1 | 2018 | 195 | 0.04 | Why? |
| Vascular Patency | 1 | 2016 | 96 | 0.04 | Why? |
| Intensive Care Units | 2 | 2021 | 29594 | 0.04 | Why? |
| Delphi Technique | 1 | 2021 | 1257 | 0.04 | Why? |
| Reproducibility of Results | 3 | 2018 | 11304 | 0.04 | Why? |
| Hydroxychloroquine | 1 | 2020 | 12447 | 0.04 | Why? |
| Neurologic Examination | 1 | 2019 | 428 | 0.04 | Why? |
| Placebos | 1 | 2019 | 629 | 0.04 | Why? |
| Research Design | 3 | 2017 | 5830 | 0.04 | Why? |
| Influenza, Human | 1 | 2021 | 10779 | 0.04 | Why? |
| Societies, Scientific | 1 | 2019 | 414 | 0.04 | Why? |
| Network Meta-Analysis | 1 | 2018 | 426 | 0.04 | Why? |
| Occupations | 1 | 2021 | 733 | 0.04 | Why? |
| Pressure | 1 | 2017 | 289 | 0.04 | Why? |
| Disclosure | 1 | 2020 | 423 | 0.04 | Why? |
| Chemotherapy, Adjuvant | 1 | 2018 | 606 | 0.04 | Why? |
| Transplantation, Homologous | 1 | 2018 | 757 | 0.04 | Why? |
| Radiography, Interventional | 1 | 2017 | 158 | 0.04 | Why? |
| Access to Information | 1 | 2020 | 483 | 0.04 | Why? |
| Pregnancy | 1 | 2017 | 23879 | 0.04 | Why? |
| Medical Records | 1 | 2017 | 513 | 0.03 | Why? |
| Probability | 1 | 2018 | 923 | 0.03 | Why? |
| Magnetic Resonance Imaging, Cine | 1 | 2019 | 669 | 0.03 | Why? |
| History, 20th Century | 1 | 2021 | 1282 | 0.03 | Why? |
| Walk Test | 1 | 2017 | 461 | 0.03 | Why? |
| Clinical Decision-Making | 2 | 2019 | 3755 | 0.03 | Why? |
| Cross-Over Studies | 1 | 2017 | 867 | 0.03 | Why? |
| Austria | 1 | 2018 | 1259 | 0.03 | Why? |
| Heart Valve Diseases | 1 | 2018 | 355 | 0.03 | Why? |
| Drug Costs | 1 | 2017 | 313 | 0.03 | Why? |
| Secondary Prevention | 1 | 2018 | 762 | 0.03 | Why? |
| Retrospective Studies | 4 | 2021 | 105322 | 0.03 | Why? |
| Multicenter Studies as Topic | 1 | 2020 | 2437 | 0.03 | Why? |
| Adolescent | 3 | 2020 | 86841 | 0.03 | Why? |
| Treatment Failure | 1 | 2019 | 2106 | 0.03 | Why? |
| Disability Evaluation | 1 | 2016 | 671 | 0.03 | Why? |
| Protein Precursors | 1 | 2016 | 425 | 0.03 | Why? |
| North America | 1 | 2017 | 1400 | 0.03 | Why? |
| Logistic Models | 2 | 2018 | 9089 | 0.03 | Why? |
| Physical Examination | 1 | 2018 | 755 | 0.03 | Why? |
| Cooperative Behavior | 1 | 2020 | 1216 | 0.03 | Why? |
| Survival Rate | 2 | 2017 | 9206 | 0.03 | Why? |
| Critical Illness | 3 | 2020 | 17281 | 0.03 | Why? |
| Betacoronavirus | 6 | 2020 | 204454 | 0.03 | Why? |
| United States Food and Drug Administration | 1 | 2019 | 1276 | 0.03 | Why? |
| Patient Acuity | 1 | 2018 | 1755 | 0.03 | Why? |
| Time | 1 | 2014 | 631 | 0.03 | Why? |
| Safety | 1 | 2019 | 1583 | 0.03 | Why? |
| Publishing | 1 | 2021 | 990 | 0.03 | Why? |
| Communicable Disease Control | 1 | 2021 | 29620 | 0.03 | Why? |
| Drug Combinations | 1 | 2021 | 3852 | 0.03 | Why? |
| Age Factors | 3 | 2018 | 21039 | 0.03 | Why? |
| Health Personnel | 1 | 2020 | 29646 | 0.03 | Why? |
| Clinical Protocols | 1 | 2021 | 2734 | 0.03 | Why? |
| Waste Water | 1 | 2021 | 2185 | 0.02 | Why? |
| Regression Analysis | 1 | 2017 | 2484 | 0.02 | Why? |
| Biomarkers | 3 | 2017 | 23361 | 0.02 | Why? |
| Length of Stay | 2 | 2017 | 11042 | 0.02 | Why? |
| Hemodynamics | 1 | 2017 | 1562 | 0.02 | Why? |
| Risk Management | 1 | 2017 | 1044 | 0.02 | Why? |
| Incidence | 2 | 2021 | 25622 | 0.02 | Why? |
| Cities | 1 | 2021 | 4937 | 0.02 | Why? |
| Thromboembolism | 1 | 2021 | 2101 | 0.02 | Why? |
| Sex Factors | 2 | 2017 | 11014 | 0.02 | Why? |
| Recovery of Function | 1 | 2018 | 2461 | 0.02 | Why? |
| Activities of Daily Living | 1 | 2016 | 1530 | 0.02 | Why? |
| Pain Management | 1 | 2016 | 854 | 0.02 | Why? |
| Antiviral Agents | 1 | 2021 | 41703 | 0.02 | Why? |
| Cost-Benefit Analysis | 1 | 2017 | 2259 | 0.02 | Why? |
| Educational Status | 1 | 2014 | 1451 | 0.02 | Why? |
| Surveys and Questionnaires | 3 | 2021 | 43792 | 0.02 | Why? |
| Odds Ratio | 1 | 2019 | 5861 | 0.02 | Why? |
| Recurrence | 1 | 2017 | 3675 | 0.02 | Why? |
| Electrocardiography | 1 | 2021 | 3957 | 0.02 | Why? |
| Perioperative Care | 1 | 2017 | 1329 | 0.02 | Why? |
| Needs Assessment | 1 | 2017 | 2352 | 0.02 | Why? |
| Forecasting | 1 | 2021 | 4492 | 0.02 | Why? |
| Risk | 1 | 2018 | 5288 | 0.02 | Why? |
| Blood Glucose | 1 | 2020 | 3642 | 0.02 | Why? |
| Antihypertensive Agents | 1 | 2018 | 1962 | 0.02 | Why? |
| Hypoglycemic Agents | 1 | 2018 | 2165 | 0.02 | Why? |
| Health Surveys | 1 | 2016 | 2841 | 0.02 | Why? |
| Self Report | 1 | 2017 | 3802 | 0.02 | Why? |
| Pilot Projects | 1 | 2017 | 5182 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2017 | 6543 | 0.02 | Why? |
| Early Diagnosis | 1 | 2014 | 2443 | 0.02 | Why? |
| Health Status | 1 | 2018 | 3259 | 0.02 | Why? |
| Decision Making | 1 | 2019 | 3132 | 0.02 | Why? |
| Inpatients | 1 | 2020 | 5161 | 0.02 | Why? |
| Hypoxia | 1 | 2019 | 3626 | 0.02 | Why? |
| Diagnosis, Differential | 1 | 2018 | 7220 | 0.02 | Why? |
| Echocardiography | 1 | 2017 | 3661 | 0.02 | Why? |
| Germany | 1 | 2018 | 9196 | 0.02 | Why? |
| Liver Cirrhosis | 1 | 2014 | 1810 | 0.01 | Why? |
| Heart Diseases | 1 | 2018 | 3503 | 0.01 | Why? |
| Mortality | 1 | 2018 | 7132 | 0.01 | Why? |
| Longitudinal Studies | 1 | 2016 | 9893 | 0.01 | Why? |
| Spain | 1 | 2019 | 15545 | 0.01 | Why? |
| Physicians | 1 | 2019 | 4214 | 0.01 | Why? |
| Young Adult | 2 | 2020 | 93724 | 0.01 | Why? |
| Heart Failure | 1 | 2017 | 6638 | 0.01 | Why? |
| Prevalence | 1 | 2017 | 25773 | 0.01 | Why? |
| Quarantine | 1 | 2021 | 18418 | 0.01 | Why? |
| Hospital Mortality | 1 | 2017 | 22087 | 0.01 | Why? |
| RNA, Viral | 1 | 2021 | 32276 | 0.01 | Why? |
| Severity of Illness Index | 1 | 2021 | 48226 | 0.01 | Why? |
| United States | 1 | 2019 | 46150 | 0.01 | Why? |
| Child | 1 | 2019 | 70012 | 0.01 | Why? |
| Neoplasms | 1 | 2017 | 17251 | 0.01 | Why? |